Protara Posts $21.7 Million Third-Quarter Loss Despite Slightly Beating Estimates
Key Facts
Protara Therapeutics said on November 6, 2026, that it posted a net loss of $21.7 million, or $0.35 a share, in the third quarter, compared with a loss of $13.3 million and $0.31 a share in the same period a year earlier. The per-share loss was below the consensus estimate of $0.3657, a positive difference of $0.0157, according to MarketBeat data. That means the company narrowly beat estimates as its net loss widened year over year. Four analysts surveyed by Zacks estimated an average loss of 37 cents a share, according to the Associated Press. The results put spending on experimental-therapy development and available liquidity at the center of investor attention on the company.
Unrestricted cash and equivalents and marketable debt securities totaled $143.1 million on September 30, 2026, the company said. Protara said it expects those resources to fund operations and planned milestones through 2028. The company’s estimate sets a financial timeline for its clinical and operating programs, but remains its own forecast. In August, Protara said those assets totaled $161.9 million on June 30 and also expected them to fund operations and planned milestones through 2028. The comparison between the two dates shows a decline in cash and marketable securities during the period, while the company maintained the same stated funding horizon.
Research and development expenses rose to $16.8 million in the third quarter from $9.6 million in the same period a year earlier. The company attributed the increase mainly to a $4.4 million rise in direct clinical-trial costs and a $2.0 million increase in personnel-related expenses. Research expenses not tied to a specific program also rose by $0.8 million, mainly related to manufacturing its experimental therapy TARA-002 and quality controls. Separately, general and administrative expenses rose to $6.3 million from $5.2 million. The company said the increase in that category was mainly tied to a $0.6 million rise in personnel expenses and a $0.6 million increase in other general and administrative expenses.
In a move related to manufacturing TARA-002, Protara on November 4 entered an agreement to buy manufacturing assets from Novix Innovations for $8.75 million. The purchased assets are related to manufacturing the therapy, according to the company’s November 6 statement. The agreement comes as the company said manufacturing costs related to the program contributed to higher research and development expenses during the quarter. Protara is developing TARA-002 to treat non-muscle-invasive bladder cancer and lymphatic malformations. The therapy is experimental and has not yet received marketing approval, according to the company’s disclosure.
On its trials, Protara said it expects to complete enrollment in the registered cohort of the ADVANCED-2 trial for patients with non-muscle-invasive bladder cancer who did not respond to BCG treatment by the end of 2026. In August, the company had expected to complete enrollment during the fourth quarter of the same year. It also said enrollment in the registered STARBORN-1 trial for lymphatic malformations is expected to be completed in early Q1 2027. The company added that it expects to begin submitting a rolling biologics license application for TARA-002 to treat lymphatic malformations in the second half of 2027. These timelines link progress on the program to trial enrollment and the regulatory steps the company has announced.
In the THRIVE-3 trial, the company completed enrollment in the Phase 2b dose-confirmation cohort, which included 24 patients. Protara described the phase as an open-label dose-confirmation trial and said it still targets announcing interim results during Q4 2026. That timing gives investors a near-term milestone to track for one of the company’s programs, alongside TARA-002 trial enrollment timelines. Interim STARBORN-1 data, based on an April 10, 2026, data cutoff, showed clinical success in 10 of the 12 participants who completed treatment and 10 of 10 evaluable patients. The seven participants who reached the Week 32 assessment remained disease-free at that cutoff, according to the company’s previous disclosure.
The stock fell 9.36% in the November 5 session, before the results announcement, and closed at $2.130, according to Investing.com data. The closing price matches the $2.13 level in EL7 data for that day. In its second-quarter 2026 results, the company had posted a net loss of $21.7 million, or $0.36 a share, compared with $15.0 million and $0.35 a share in the second quarter of 2025. It also reported cash and marketable debt securities of $161.9 million on June 30, with funding expected through 2028. Protara’s next announced milestones center on completing ADVANCED-2 enrollment by the end of 2026, THRIVE-3 interim results in Q4, and then completing STARBORN-1 enrollment in early 2027.